Roquefort Therapeutics (LON:ROQ) Shares Down 8.1% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 8.1% during trading on Monday . The stock traded as low as GBX 1.50 ($0.02) and last traded at GBX 1.50 ($0.02). Approximately 430,839 shares traded hands during trading, a decline of 81% from the average daily volume of 2,247,898 shares. The stock had previously closed at GBX 1.63 ($0.02).

Roquefort Therapeutics Stock Down 8.1%

The business has a fifty day moving average of GBX 1.68 and a 200 day moving average of GBX 2.54. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm has a market cap of £1.91 million, a P/E ratio of -1.24 and a beta of 0.05.

Roquefort Therapeutics (LON:ROQ) last issued its earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.